Results 71 to 80 of about 28,652 (194)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

ORAL, ONCE-DAILY RIVAROXABAN FOR THE PREVENTION OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY: A META-ANALYSIS OF THREE PIVOTAL STUDIES [PDF]

, 2008
Alexander G.G. Turpie, Michael R. Lassen, Ajay K. Kakkar, Bengt I. Eriksson, Frank Misselwitz, Tiemo J. Bandel, Martin Homering, Torsten Westermeier, Michael Gent   +8 more
openalex   +1 more source

A single institution’s experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation

Proceedings of Singapore Healthcare, 2018
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has not been well studied. This study aims to evaluate the clinical
Li Xin Chan, Yee May Wong, Pow-Li Chia, Zhen Liang Kek   +3 more
doaj   +1 more source

New drugs: Rivaroxaban [PDF]

, 2009

openalex   +1 more source

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective [PDF]

, 2011
A Alvarado Duran, Nishan Sengupta, Α. Διαμαντόπουλος, Fiona Forster, Louis M. Kwong, Michael Lees   +5 more
openalex   +1 more source

Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model [PDF]

, 2011
Anne Godiér, Anastasia Miclot, Bernard Le Bonniec, Marion Durand, Anne‐Marie Fischer, Joseph Emmerich, Catherine Marchand‐Leroux, Thomas Lecompte, Charles Marc Samama   +8 more
openalex   +1 more source

Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban [PDF]

, 2011
Cyrus D. Jensen, A. Steval, Paul Partington, Mike Reed, Susanne Müller   +4 more
openalex   +1 more source

PCV8 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison with Dabigatran Under the Brazilian Private Health Care System Perspective [PDF]

, 2011
Alexandre Schiola, A.P. Silva, N.B. Santoni, L. Paladini, V Teich, C. Pepe, Marinalva Soares de Oliveira Rocha   +6 more
openalex   +1 more source

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [PDF]

, 2012
Peter C. Netzler
openalex   +1 more source

Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database [PDF]

, 2012
Sally Lee, Brigitta U. Monz, Andreas Clemens, Martina Brueckmann, Gregory Y.H. Lip   +4 more
openalex   +1 more source